Codagenix

Edit info

Founded: 2011

Location: Farmingdale, NY

Employee range: 11 - 50

Clinical stage: Clin3

Therapy area: COVID-19

Drug types: INF, VAC, ONC

Lead product: CoviLiv

Funding: $25M B Feb 2023; $20M Feb 2020; $2M A Jun 2015; $322K Dec 2014

Investors: Serum Institute of India Pvt. Ltd., Euclidean Capital, Adjuvant Capital

codagenix.com

linkedin.com

job board

Drug notes:

RSV CodaVax Clin1 RSV, Clin0 pediatric RSV; Universal Influenza CodaVax Clin1 influenza; CDX-DENV Clin0 Dengue; CDX-ZiKV Clin0 Zika; undisclosed Clin0 yellow fever; CodaLytic Clin0 breast cancer; CDX-Onc Clin0 solid tumors

About:

Codagenix is developing live-attenuated viral vaccines using codon deoptimization technology. Live-attenuated viral vaccines involve giving patients an engineered dose of the virus that have been modified to prevent severe infection, but still trigger antibody production giving the patient protection against future exposure. Codagenix is leveraging their proprietary synthetic biology-driven approach to design hundreds of genetic edits that attenuate viral activity. Key to their approach is codon deoptimization - a strategy that prevents production of viral proteins which the virus needs to replicate. With this approach, Codagenix can deliver solutions for infectious disease and cancer that have the immunity benefits of live-attenuated viruses and are safe and scalable.

Jobs:

Main

Contact: recruit@workinbiotech.com